The capital injection bolsters Antengene’s cash reserves as it advances the Phase I ATTRACT study for ATG-201. China’s National Medical Products Administration cleared the investigational drug application for this trial in June, and the company is currently preparing to expand clinical development into Australia. Beyond the initial $60 million, the agreement includes an additional $20 million in near-term milestones, alongside potential success-based payments and tiered royalties on future sales.

ATG-201 utilizes Antengene’s proprietary AnTenGager platform, specifically employing steric hindrance masking to improve precision when eliminating CD19-expressing B cells. By leveraging the body’s immune system through CD3 and CD19 interactions, the therapy aims to provide a potent alternative for patients with unmet medical needs. This partnership remains a cornerstone of Antengene’s strategy to monetize its R&D pipeline while maintaining its broader portfolio of clinical-stage oncology and autoimmune assets.